Takeda farms out cancer drug alisertib to Puma Biotech
pharmaphorum
SEPTEMBER 21, 2022
Enter Puma Biotech, which is paying a modest $7 million upfront for rights to alisertib (formerly MLN8237) and plans to run clinical trials of the compound in breast and lung cancers. Takeda is also in line for just over $287 million in potential milestone payments, plus royalties on net sales if it reaches the market.
Let's personalize your content